Xenon Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Good morning. Welcome to our Needham's 21st Annual Healthcare Conference. Glad to have for next session the Xenon Pharmaceuticals team. We have Ian Mortimer, the company's CEO; and Sherry Aulin, the company's CFO. So happy to have you guys for a fireside chat this morning. I think 2021 was a very transformational year for Xenon, and there is a lot to look forward to in 2022 also.
So maybe if we can start off with a brief overview of the company, and then we'll jump to some questions. Ian, do you want to start off with a brief overview?
Perfect, yeah. Thanks, Serge. And thanks to you and thanks to the Needham team for hosting us today. And I think you're right, 2021 was a transformational year for us with a lot of focus on XEN1101. We had very strong data in the fall of last year, and we are building good momentum going into 2022 with some key milestones for that program this year. And I'll highlight those in a minute.
But just
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |